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ABSTRACT  
The synthesis and inhibitory potencies against botulinum neurotoxin serotype A light chain 
(BoNT/A LC) using in vitro HPLC based enzymatic assay for various steroidal, benzothiophene, 
thiophene and adamantane 4-aminoquinoline derivatives is described. In addition, the 
compounds were evaluated for the activity against BoNT/A holotoxin in mouse embryonic stem 
cell derived motor neurons. Steroidal derivative 16 showed remarkable protection (up to 89% of 
uncleaved SNAP-25) even when administered 30 minutes post intoxication. This appears to be 
the first example of LC inhibitors antagonizing BoNT intoxication in mouse embryonic stem cell 
derived motor neurons (mES-MNs) in a post-exposure model. Oral administration of 16 was well 
tolerated in the mouse up to 600 mg/kg, qd. Although adequate unbound drug levels were not 
achieved at this dose, the favorable in vitro ADMET results strongly support further work in this 
series.   
INTRODUCTION  
Botulinum neurotoxins (BoNTs) are proteins produced by the Gram-positive anaerobic 
bacterium Clostridium botulinum. They are amongst the most potent toxins known and are 
causative agents of botulism, a serious and life-threatening illness in humans and animals.1 There 
are at least seven distinct serotypes (A-G), however, three of them (A, B and E) are considered 
the most noxious in humans.2,3 The majority of efforts have been focused on identification of 
BoNT/A inhibitors with intracellular activity, because antibody-based treatments were found 
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successful only before toxin enters a neuron.4 Recent reviews have covered the in vitro - in vivo 
gap in this field,4  focusing on small molecule non-peptide inhibitors (SMNPI), potential drug 
targets and the MOA of these SMNPIs.5,6 Very recently, several approaches using SMNPIs have 
been explored by targeting the host intoxication pathways not by directly inhibiting the toxins’ 
proteolytic activity but focusing on Src family kinase signaling,7 thioredoxin reductase system8,9 
and by the development of phosphatase inhibitors that would have an impact on BoNT 
intoxication in motor neurons.10 The alternative approach was also developed, the inhibitors that 
interact with BoNT/A LC; among them the hydroxamates11 and aminoquinolines showed high 
inhibitory activities against BoNT/A LC in cell-free assays.12-16 12,13,14,15,16 Diverse cell-based 
assays have been used as more relevant methods for evaluation of new drugs capable of 
protecting SNAP-25 from BoNT/A LC cleavage.17-20 17,18,19,20 More importantly, these methods 
simulate all key steps in intoxication process, starting from holotoxin binding to the cell surface 
to cleavage of the SNARE proteins.21,17 Since there is a continuous need for discovering new 
therapeutics for treatment of BoNT/A intoxication, this method is considered to be a very helpful 
tool for narrowing the spectrum of compounds for testing in animal models. Ex vivo assays, such 
as the mouse hemidiaphragm assay for BoNT/A induced muscle paralysis are also widely used 
for evaluating new drug candidates (e.g. quinolin-8-ol inhibitors22 and EGA23).  Despite several 
attempts,23-27 23,24,25,26,27 there is still no inhibitor that is significantly effective in an animal model 
of intoxication, especially when administered post toxin injection. Recently published complexes 
of Cu(II) with dithiocarbamate and bis(thiosemicarbazone) are also only capable of extending 
time to death of BoNT/A intoxicated mice.28 Similarly, newly published mercaptoacetamide 
inhibitor ABS 252 proved to be effective in extending survival of BoNT intoxicated mice.29 
Presently, the only SMNPI with anti-BoNT/A activity in the mouse model is Dyngo-4a which 
administered 3 h post-intoxication provides 30% mice survival for 24 h.30 For the treatment of 
BoNT intoxication, it is necessary for inhibitors to reach the neuromuscular junction and enter 
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the neuronal cell. Thus, adequate drug exposure at the target tissue is key, and in vitro ADMET 
parameters such as solubility, microsomal stability, permeability and plasma protein binding can 
be used as an effective means to down select active compounds capable of providing acceptable 
PK properties.  
We designed our new BoNT/A LC inhibitors according to structure-based docking 
simulations.16 Since docking simulations indicated that besides steroids the benzothiophene 
derivatives of aminoquinoline also fit into the binding cleft of BoNT/A LC (keeping the main 
interactions with amino acid residues within the active site, c.f. Supporting information), we 
decided to investigate the contribution of other carriers to the inhibitory activity (Chart 1). 
 Here, we report on the synthesis, pharmacokinetic analysis and detailed evaluation of 
new steroidal, benzothiophene, thiophene and adamantane 4-aminoquinoline inhibitors of 
BoNT/A LC and their respective inhibitory potencies against BoNT/A holotoxin in mouse 
embryonic stem cell derived motor neurons (mES-MNs). 
 
 
 
 
 
Chart 1. General structures of investigated steroidal, benzothiophene, thiophene and adamantane 
derivatives 
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CHEMISTRY 
Continuing our search for efficient BoNT/A inhibitors, we report on new steroidal derivatives 
with improved inhibitory activities against BoNT/A LC. Here, we focus on steroidal derivatives 
with a basic amino group at C(3), varying the linker connecting the steroidal and aminoquinoline 
components. Also, we examined three other classes of aminoquinoline derivatives with 
benzothiophene, thiophene and adamantane carriers for their inhibitory activities against 
BoNT/A LC. All steroidal, benzothiophene, thiophene and adamantane derivatives were 
synthesized according to our established procedures (Schemes 1 and 3).16,31,32 All tested 
inhibitors were fully characterized and their purities were >95% (as determined by HPLC, 
Supporting Information).  
Based on our earlier findings,16 the newly synthesized steroidal inhibitors were chosen for 
essential SAR studies within the series. To that purpose, we varied the substitution at carbon 
atoms next to nitrogens, at N-C(24) and substitution at quinoline C(7) position. Steroidal 
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derivatives were obtained by reductive amination starting from C(24) alcohol derivative 3.16 
After removal of protecting group, compounds 14, 16, 17 and 19-23 were obtained in moderate 
to excellent yield (48-97%). In addition, subjecting the Boc-protected derivatives to reductive 
amination with 37% formaldehyde and NaBH3CN followed by removal of the protecting group 
afforded N-methylated derivatives 15 and 18 in acceptable yields (56-60%). Due to the presence 
of the methyl group at N-C(α), compounds 17-21 were obtained as mixture of diastereomers and 
were tested as such (vide infra). According to our docking model only C(7) (and not (C12)) 
acetoxy group is directing structural element featuring the Zn2+ chelation so favorably 
contributing to inhibitor’s diving into catalytic cleft (Fig. S11-S13).16 The inhibitor 24 (68%) 
was obtained by hydrolysis of acetoxy groups in 16 with potassium hydroxide in methanol 
(Scheme 1).  
Scheme 1. Synthesis of novel steroidal derivatives 14-24 
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Steroidal derivative 30 with the amide functional group next to quinoline was prepared in order 
to explore the effect of changes in pKa and conformation on inhibitory activity. N-Boc protected 
derivative 29 was obtained in 43% yield by reductive amination of steroidal C(24) aldehyde and 
amine 28 (prepared in few steps starting from 4,7-dichloroquinoline). It has been noticed that 
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amine 28 decomposes to 25 and pyrrolidine-2-one, therefore, it was used in next step without 
detailed characterization. The final compound 30 was obtained in good yield (80%) after 
removal of the Boc protecting group (Scheme 2). 
Scheme 2. Synthesis of steroidal derivative 30 
N
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C, 3.5 h; ii) 4-chlorobutanoyl chloride, Et3N, CH2Cl2, 0 
o
C to r.t.; iii) NaN3, 
DMF, 80 
o
C; iv) Ph3P, THF, H2O, 65 
o
C; v) 1) aldehyde, dry MeOH, 2) NaBH4; vi) CF3COOH, CH2Cl2
iii)
28: 66%
 
Synthesis of novel benzothiophene and thiophene derivatives is presented in Scheme 3. 
Benzothiophene and thiophene derivatives 33, 34, 42-45 and 50 were obtained by reductive 
amination from corresponding aldehydes (31, 39-41 and 49) in moderate yield (12-77%). 
Compound 47 was obtained from 45 after removal of TMS-group in moderate yield. 
Benzothiophene and thiophene N-methyl tertiary amino derivatives, 37, 38 and 48 were 
synthesized by reaction of formaldehyde with secondary amines 35, 36 and 46 respectively, 
reported in our previous work.31,33  
Scheme 3. Synthesis of novel benzothiophene (33, 34, 37, 38) and thiophene (42-44, 47, 48, 50) 
derivatives 
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i) 1) aminoquinoline/aldehyde, AcOH glac, MeOH/CH2Cl2, rt, 2 h 2) NaBH4, rt, 12 h; ii) HCHO, MeOH, ZnCl2, NaBH3CN; iii) K2CO3, MeOH, rt
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46: n=5, R=CN, R1=H, X=H (26%)
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48: n=5, R=CN, R1=Me, X=H (50%)
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Syntheses of novel adamantane derivatives are presented in Scheme 4. Adamantane derivatives 
with tertiary nitrogen 56-65, 68 and 69 were obtained using the same procedures as mentioned 
above in moderate to excellent yield (55-93%) after coupling of prepared amines (51- 55, AQ11, 
AQ7, AQ8)13,32,34 to corresponding aldehydes. Key reaction for synthesis of adamantane 
derivatives 77-82 was the Pd-mediated Buchwald coupling of previously prepared amines (70-
75)32 to 4-chloroquinoline in moderate to excellent yield (44-91%). Compounds 84 and 85 were 
obtained in high yield by methylation of compounds 78 and 83, respectively.  
 
 
 
 
Scheme 4. Synthesis of novel adamantane derivatives 56-69, 77-82, 84 and 85 
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56: n=0, m=1, R=Me, R1,R2=H, X=Cl (82%)
57: n=1, m=1, R=Me, R1,R2=H, X=Cl (87%)
58: n=2, m=1, R=Me, R1,R2=H, X=Cl (93%)
59: n=0, m=1, R,R2=Me, R1=H, X=Cl (91%)
60: n=1, m=1, R,R2=Me, R1=H, X=Cl (87%)
61: n=0, m=2, R=Me, R1,R2=H, X=Cl (89%)
62: n=1, m=2, R=Me, R1,R2=H, X=Cl (84%)
63: n=2, m=2, R=Me, R1,R2=H, X=Cl (86%)
64: n=0, m=2, R,R2=Me, R1=H, X=Cl (93%)
65: n=1, m=2, R,R2=Me, R1=H, X=Cl (80%)
66: n=1, m=1, R,R1,R2,X=H (60%)
67: n=1, m=2, R,R1,R2,X=H (70%)
68: n=1, m=1, R=Me, R1,R2,X=H  (72%)
69: n=1, m=2 R=Me, R1,R2,X=H (55%)
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32
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32
 
75: n=2, m=2, R2=H, R1=Me
32
76: n=1, m=1, R2=Me, R1=H
32 
77: n=0, m=1, R,R2=H, R1=Me (60%)
78: n=1, m=1, R,R2=H, R1=Me (91%)
84: n=1, m=1, R,R1=Me, R2=H (89%)
79: n=2, m=1, R,R2=H, R1=Me (44%)
80: n=0, m=2, R,R2=H, R1=Me (50%)
81: n=1, m=2, R,R2=H, R1=Me (51%)
82: n=2, m=2, R,R2=H, R1=Me (53%)
83: n=1, m=1, R,R1=H, R2=Me (73%)
32
85: n=1, m=1, R,R2=Me, R1=H (70%)
ii)
ii)
i) 1) aminoquinoline/aldehyde, AcOH glac, MeOH/CH2Cl2, rt, 2 h 2) NaBH4, rt, 12 h; ii) HCHO, MeOH, ZnCl2, NaBH3CN; iii) 
aldehyde, NaBH(OAc)3, CH2Cl2, rt, 24 h; iv) 4-chloroquinoline, Pd(OAc)2, SPhos, K3PO4, dioxane, 85 
o
C, 24 h
 
RESULTS  
Recently, we discovered steroidal bis-aminoquinoline (bis-ACQ) inhibitors with 90-97% 
BoNT/A LC inhibition and Ki values within the range 0.103-0.389 µM (such as 1, Chart 1).16 
However, several comments regarding our hit compounds should be considered. Simplifying the 
original structure should be desired since the synthesis of bis-ACQ derivatives and purification 
thereof is rather demanding task. In addition, the compounds with MW > 900, although of 
natural product origin, are not commonly considered drug-like and could have difficulties in 
reaching the target as well. Therefore, we have chosen the compound 2 (Chart 1),16 with IC50 = 
0.81 µM and Ki = 3.22 µM in HPLC-based assay and 77% of SNAP-25 protection at 30 µM in 
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pre-intoxication scenario in embryonic chicken spinal primary neurons as very promising 
starting point for further improvement of the steroidal inhibitors.  
 
Evaluation of Inhibitory Activity Against BoNT/A LC.  
Inhibitory activities against BoNT/A LC in proteolytic and against holotoxin in cell-based assay 
are presented in Table 1. In vitro activities for all other compounds that were evaluated only 
against BoNT/A LC are given in Supporting Information (Table S1).  
We employed a well-defined 17-mer peptide (termed P39, acetyl-SNKTRIDEANQRATKML-
amide, that contains the SNAP-25 scissile bond)35 HPLC-based proteolytic assay. Synthesized 
steroidal derivatives have shown BoNT/A LC inhibition up to 85% at a standard 20 µM 
concentration (compound 18) and IC50 values ranging from 0.7-7.1 µM (Table 1, Table S1). Our 
control compound 1, in the current proteolytic HPLC-based assay showed 90% inhibition of 
BoNT/A LC at 20 µM, in excellent agreement with results reported previously (95% of 
inhibition).16 Compound 24 with hydroxy groups at C(7) and C(12), with 48% inhibition of 
BoNT/A LC appeared to be much less potent than other steroidal derivatives. The negative effect 
of the amide functionality on BoNT/A LC inhibition (30, 37%) was also observed. Introduction 
of a methyl group into the linker or secondary nitrogen and changing its position, as well as the 
variations in the presence of chlorine atom at the quinoline moiety influenced the inhibitory 
activity to certain extent.  
Benzothiophene derivatives showed good inhibition activities too, with IC50 values ranging 
within 3.3-10.2 µM, thus being comparable to the steroidal series. By changing the position of 
cyano group from C(6) to C(5) the inhibition at 20 µM concentration was sharply improved 
(Table 1, Table S1, compounds 36 (61%), 87 (75%), 86 (84%) vs 88 (23%), 89 (8%)). 
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Derivatives with cyano group instead of fluorine atom at C(5), showed higher degree of 
inhibition (Table 1, Table S1, compounds 86 (84%), 87 (75%) vs 35 (34%), 90 (56%)), while the 
compounds without tertiary nitrogen appeared to be more active at 20 µM concentration than 
their methylated analogs (Table 1, Table S1, compounds 91 (69%), 36 (61%) vs 92 (48%), 38 
(27%)). In thiophene series, the most potent inhibitors proved to be 46 and 93 with cyano 
substituent and long methylene linker (6 and 8 methylene groups and 70-80% and 77% of 
inhibition, respectively). Compound 46 (MV150) with 70-80% of inhibition has been utilized as 
positive control, for evaluating the performance of the 17-mer HPLC-based proteolytic assay. 
Changing the position of aminoquinoline linker connection to phenyl moiety from para- to meta- 
had no significant effect on inhibitory activity (Table 1, 46 (70-80%) vs 50 (68%)). Improvement 
of the inhibitory activity was observed in derivatives without chlorine atom at C(7) position of 
aminoquinoline or without tertiary nitrogen (Table 1, Table S1, compounds 93 (77%), 46 (70-
80%) vs 94 (14%), 95 (30%) and 96 (35%), 48 (55%)). In addition, cyano derivatives were found 
to be superior inhibitors than their ethynyl analogs (Table 1, Table S1, compounds 97 (36%), 46 
(70-80%) vs 47 (19%), 98 (53%)). Examined adamantane derivatives bearing chlorine atom on 
aminoquinoline moiety proved to be more active in the HPLC-based proteolytic assay than their 
des-chloro analogs (Table 1, Table S1, compounds 57 (71%), 60 (67%), 99 (64%) vs 69 (31%), 
85 (51%), 100 (42%) and other analogs), and that differs from the previously mentioned 
thiophene series. Tertiary nitrogen and chlorine atom at C(7) of aminoquinoline moiety together 
had the most favorable effect on the inhibitory activity (57 and 60, 71% and 67% of inhibition, 
respectively, Table 1). 
In addition, experimental logD values are presented in Table 1. LogD values are obtained using 
reversed-phase thin-layer chromatography at two different pH: pH=1 (MeOH/HCl (70/30)) for 
compounds 14-19, 24, 46, 50, 93, 96 and 101 and pH=10 (acetone/NH3/H2O (85/5/10)) for 
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compounds 34, 36-38, 57, 60, 86, 87, 91, 102-106.36 For compound 16 logD was also determined 
at physiological pH=7.3, using shake-flask method (octanol/TBS buffer).37-39 37,38,39 
Table 1. Inhibitory activities against BoNT/A LC and holotoxin in proteolytic and cell-based 
assaya 
Compound
b
 exp LogD
c
 
In vitro 
proteolytic 
assay  
% inh 
BoNT/A LC 
at 20 µM; IC50 
(µM) 
mES-MNs pre 
intoxication 
% of full 
length SNAP-
25 (10 µM; 20 
µM) 
mES-MNs post 
intoxication at 
20 µM % of full 
length SNAP-25 
(30 min; 60 min) 
14 
2.14 
(pH=1) 
80; 5.7 28; 67 48; 49 
15 
2.11 
(pH=1) 
52; 1.5 70; 69 - 
16  
2.55 
(pH=1); 
2.07 
(pH=7.3)d 
66; 4.5 72; 88 64; 45 
17 
2.28 
(pH=1) 
71; 2.7 67; 69 38; 22 
18 
2.38 
(pH=1) 
85; 0.7 20; 41 - 
19 
2.21 
(pH=1) 
75; 3.0 86; 87 50; 22 
24 
2.97 
(pH=1) 
48 46; 58e 49;e  - 
34 
3.85 
(pH=10) 
75; 7.4 58; 68 16; 17 
36 
3.67 
(pH=10) 
61; 10.2 34; 53 - 
37 
3.98 
(pH=10) 
46 44; 55 - 
38 
3.42 
(pH=10) 
27 59; 64 - 
86 
3.67 
(pH=10) 
84; 4.6 21; 26 - 
87 
3.85 
(pH=10) 
75; 3.3 36; 43 - 
91 
3.98 
(pH=10) 
69; 8.8 62; 62 - 
46 3.08 70-80; 3.4 22; 48 - 
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(pH=1) 
50 
3.08 
(pH=1) 
68; 8.7 46; 71 - 
93 
3.42 
(pH=1) 
77; 6.8 31; 70 20; 19 
96 
3.33 
(pH=1) 
35 54; 60 34; 22 
101 
2.93 
(pH=1) 
67; 9.3 18; 39 - 
57 
3.24 
(pH=10) 
71; 8.8 51; 56 46; 39 
60 
3.47 
(pH=10) 
67; 11.7 63; 72 15; 16 
68 - 30 30; 31 - 
81 - - 23; 24 - 
85 - 51; 5.2 47; 46 - 
102 
3.40 
(pH=10) 
65; 2.7 29; 30 - 
103 
4.33 
(pH=10) 
2 30; 29 - 
104 
3.24 
(pH=10) 
15 31; 35 - 
105 
3.09 
(pH=10) - 24; 23 - 
106 
4.13 
(pH=10) - 30; 32 - 
Negative 
control 
DMSO 
- - 100 100 
Positive 
control 
1 
- 90; 12.4f 70; 84 36; 20 
aResults are given as mean value of three independent experiments. bSyntheses of compounds 
36, 46, 86, 87, 91, 93, 96 and 101 were reported in our previous work.31 Syntheses of compounds 
102-106 were reported in our previous work.32 cExperimental LogD using reversed-phase thin-
layer chromatography at pH=1 (MeOH/HCl (70/30)) or pH=10 (acetone/NH3/H2O (85/5/10)). 
dExperimental LogD in octanol/TBS buffer at pH=7.3 using shake-flask method. eCompound 24 
was tested at 8 and 16 μM in pre-intoxication model and at 16 μM in 30 minutes post-
intoxication model only; fIn previous test the inhibition was 95.46% and Ki = 0.285µM.
16  
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Inhibitory Activity Against Holotoxin in mES-MNs.  
Pre-intoxication model 
Based on the activity in primary screen and structural diversity (Table 1, Table S1), 30 
compounds were chosen for secondary screening in cell-based assay in mouse ES-cell derived 
motor neurons (mES-MNs) in pre-intoxication model at two concentrations – 10 and 20 µM 
(Table 1). SNAP-25 protein cleavage was measured by Western-blot analysis. In this model, 
compounds were added 30 minutes prior to holotoxin (500 pM) and intoxicated for 4 hours. 
Inhibitors tested during BoNT/A challenge in mES-MNs in pre-intoxication model were found to 
afford uncleaved SNAP-25 up to 88% at 20 µM concentration (compound 16), with steroidal 
compounds being generally the most promising.  
In contrast to in vitro results, using this assay we can substantially differentiate our steroidal 
inhibitors from benzothiophene derivatives, which were capable to protect SNAP-25 from 
cleavage up to 68% at 20 µM concentration. Another issue is important to note – benzothiophene 
derivatives (36, 86 and 87) with cyano instead of fluorine substituent were much less active 
despite the high percent of inhibition in HPLC-based assay. In addition, in this model the 
compound 38, shows significantly higher protection of SNAP-25 in comparison with non-
methylated analogues, although it would be eliminated based on its poor inhibitory activity 
(27%) in primary screening. Three thiophene derivatives have shown to be capable of protecting 
SNAP-25 from cleavage more than 60% at 20 µM concentration (50, 93 and 96), while 
adamantane derivatives were found to be less active, despite promising results obtained in 
primary screening. Only one adamantane 60, showed 72% protection of SNAP-25 at 20 µM. 
Twelve compounds with good results obtained in pre-intoxication model (56-88% SNAP-25 
protection at 20 µM concentration, Table 1) were subjected to pre-exposure dose-response 
experiment in concentration range from 0.1 to 20 µM (Figure 1). The results obtained in dose-
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response experiment at 20 µM concentration are similar to those obtained in the initial 
experiment at two concentrations, given in Table 1. The obtained dose-response results clearly 
indicate that introduction of chlorine atom at C(7) position of quinoline moiety highly improved 
the activity of steroidal inhibitors (16 vs 14; IC50 ~ 10 µM vs IC50 = 10-20 µM, respectively). 
Another pair of derivatives, 19 with methyl group next to N-C(24) and 17 with methyl group 
next to quinoline moiety, also merit attention. Significantly higher protection of SNAP-25 is 
observed with 19 at 20 µM concentration, while at lower concentrations both derivatives 
exhibited comparable inhibitory activity. Except mentioned four steroidal derivatives, compound 
1 showed remarkable activity in pre-intoxication scenario (IC50 < 10 µM). As the inhibitor 24 
could arise as putative metabolite in vivo, despite its lower activity in HPLC-proteolytic assay 
compared to other steroidal derivatives, we were intrigued by moderate activity of this 
compound in pre-intoxication model (58% at 16 μM, Table 1). Tested at nine concentrations 
0.25 to 64 µM it also showed dose-dependent behavior, with IC50 =8-16 µM (Figure S1, Table 
S5). Benzothiophene derivatives 34 and 38 showed IC50 values in 10-20 µM range. In addition, 
three thiophene (50, 93 and 96) and two adamantane (57 and 60) 4-aminoquinoline derivatives 
were evaluated in dose-dependent pre-intoxication model, in order to examine the scope of 
carriers coupled to aminoquinoline moiety. To our pleasure, not only steroidal and 
benzothiophene aminoquinolines showed remarkable activities in dose-dependent manner, but 
also thiophene and adamantane derivatives. As one can find in Figure 1, 60 has shown the 
highest protection of SNAP-25 at 20 µM concentration (90%) and IC50 < 10 µM. Good dose-
response and high percent of inhibition is also seen for 93 and 96 (IC50 = 10-20 µM and IC50 = 5-
10 µM, respectively).  
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Figure 1. Protection of SNAP-25 in mES-MNs in pre-intoxication model (results are given as 
mean value of three independent experiments +/- SEM, values given in Table S2).  
 
Post-intoxication model 
The most effective derivatives were tested post-symptomatically (in triplicate, 30 and 60 minutes 
following 500 pM holotoxin administration) at 20 µM concentration (Figure 2). Compound 60, 
which was the foremost candidate in pre-intoxication model, unfortunately failed in post-
exposure model with only 15% of intact SNAP-25. From all tested derivatives, compound 16 
highlights with 64% of SNAP-25 cleavage protection when administered 30 minutes post-
intoxication, and 45% protection when neurons were treated 60 minutes after BoNT/A 
administration. Other derivatives were significantly less active, with steroidal series still being 
the most promising.  
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Figure 2. Protection of SNAP-25 in mES-MNs in post-intoxication model at 20 µM (results are 
given as mean value of three independent experiments +/- SEM, values given in Table S3). 
Since compound 16 showed excellent behavior in post-intoxication scenario (Figure 2 and Figure 
S2, Table S6), and compound 24 is considered as a potential metabolite which is reasonable to 
expect to be formed in mouse gut and liver, we subjected both 16 and 24 to 30 minutes post-
exposure dose-response experiment. Compounds were tested in duplicate at 9 concentrations, 
starting from 0.25 µM → 64 µM (Figure 3). In this run 16 exhibited a dose-dependent protection 
of SNAP-25, with IC50 ~8 µM. To the best of our knowledge, this is the most active small-
molecule inhibitor of BoNT/A LC in post-intoxication scenario in mES-MNs (89% of full length 
SNAP-25 at 32 μM). The activity of compound 24 in mES-MNs (69% full length SNAP-25 at 64 
µM) was somewhat surprising; however, observation that both, the compound 16 and its putative 
metabolite were active in mES-MNs strongly supports further examination of biological activity.   
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Figure 3. Protection of SNAP-25 in mES-MNs by compounds 16 and 24 administered 30 min 
post-intoxication – dose response experiment 0.25 to 64 µM (results are given as mean value of 
two independent experiments +/- SEM, values given in Table S4). IC50 ~8 µM. Compound 16 
showed potential toxicity at 64 μM, since GAPDH (used as loading control) levels were lower. 
In the independent dose-response experiment, 16 showed protection of SNAP-25 up to 64% at 
20 µM (Figure S2, values given in Table S6). 
 
Toxicity studies.  
In vivo toxicity studies of several derivatives subjected to post-intoxication assay was estimated 
in a mouse model. As can be seen from Table 2, 16, 34, 93 and 96 proved to be completely non-
toxic at the given dose (all 5 mice survived 30 days after administration and showed normal 
appearance and behavior).  
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Table 2. Toxicity study in micea 
Compound 
(at 3 × 160 mg/kg dose) 
Mice alive/ 
Total mice 
16 5/5 
19 3/5 
34 5/5 
57 4/5 
60 3/5 
93 5/5 
96 5/5 
aGroups of five healthy mice were treated per os (p.o.) for three consecutive days with 
aminoquinolines suspended in 0.5% hydroxyethylcellulose - 0.1% Tween 80. Individual mouse 
behavior and appearance was monitored two times a day for 30 days. 
 
In the separate host toxicity studies, two groups of 5 healthy mice were subjected to oral 
administration of the compound 16 at higher concentrations (400 and 600 mg/kg, single dose), 
and even at the highest applied concentration, 16 proved to be non-toxic (all 5 mice survived 30 
days after administration and showed normal appearance and behavior). 
Pharmacokinetic Analysis of Compound 16. 
ADMET parameters  
Given its ability to antagonize BoNT/A in mES-MNs in post-intoxication model (in full 
accordance with previous step analyses), 16 appeared as the best candidate for further testing. 
ADMET parameters for this compound are presented in Table 3. Compound 16 showed good 
stability in both human and mouse liver microsomes (half-life >60 min) and very good stability 
in human plasma (>85% remaining at 1 h). It showed solubility >50 µg/mL (Table 3) as 
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determined by laser nephelometry and confirmed by more precise shake-flask method with 
spectrofluorimetric detection (640 µg/mL). In MDR1-MDCK permeability assay, 16 showed 
excellent tissue penetration (45.3×10-6 cm/s in A→B direction and 24.6×10-6 cm/s in B→A 
direction). It acts as moderate to poor inhibitor of five CYP450 enzymes (which play important 
role in the drug metabolism). One in vitro parameter possibly limiting this compound as potential 
drug is high plasma protein binding, >99% according to equilibrium dialysis method. However, 
the efficacy of the drug transport could not be attributed to the PPB only; instead, the binding 
constants with major transporters in the blood should be considered. In addition to dialysis, the 
interaction between 16 and HSA and AGP proteins has been studied by monitoring the changes 
in fluorescence spectrum of HSA and AGP upon addition of increasing amounts of 16 
(Ksv=(4.56±0.27)×10
4 for HSA; Ksv=(6.99±0.25)×10
5 for AGP).   
Table 3. ADMET parameters for compound 1640 
ADMET Properties 
Purity of the sample (%)a >90 
Solubility at pH 7.4 (µg/mL)b >50 
Stability – Microsomesc 
T1/2 (min) >60 
CLint (µL/min/mg) <23 
Stability – Human plasma (% remaining at 1 h)d >85 
CYP450 Inhibition IC50 (µM)
e,f 1-10 
MDR1-MDCKg 
Papp (a-b, 10
-6 cm/s) 45.3 
Pgp Efflux Ratio 0.54 
Plasma protein binding (%)h >99 
aPurity analysis was determined by LC-MS/MS. bSolubility (n=3) was determined using laser 
nephelometry to measure light scattering. cSubstrate depletion experiments were performed by 
incubating test compound with liver microsomes (human and mouse) for 1 hour at 37°C. dPlasma 
stability was determined following incubation for 1 hour at 37°C. eThe IC50 value was 
determined from the net fluorescent signal from incubation at 37°C for a set time with an active 
cytochrome P450 enzyme and a fluorescent probe substrate. fFor CYP3A4/BQ (1.1 µM), 
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CYP3A4/DBF (1.2 µM), CYP3A4/BFC (1.4 µM), CYP2C19/CEC (5 µM) and CYP2D6/AMMC 
(>10 µM). gThe MDR1/MDCK apparent permeability constant (Papp) was determined after 1 
hour incubation at 37 °C of the compound on the apical compartment (A to B) or basolateral 
compartment of the cell monolayer (B to A). The Efflux Ratio is the ratio of the Papp in the B to 
A direction divided by the Papp in the A to B direction. 
hAccording to equilibrium dialysis 
method. 
 
In Vivo Mouse Pharmacokinetics  
Aminoquinoline 16 was selected for determination of concentration levels in mouse serum and 
evaluation of plasma protein binding due to its promising activity in mES-MNs, non-toxicity, 
and very good ADMET properties. Compound 16 was dosed orally, in a single dose, at two 
different concentrations – 400 and 600 mg/kg to groups of 7 and 6 mice, respectively. For both 
doses, maximal concentration of the drug in the blood was determined by UPLC-MS/MS in 
samples previously treated with acetonitrile (15 → 120 min, Table 4 and Figure 4).  
 
Table 4. Concentration levels of 16 in mouse serum at different time points following oral 
administration at two different doses.a 
Time (min) 
400 mg/kg dose 
µg/mL (µM) 
600 mg/kg dose 
µg/mL (µM) 
15 2.3 (3.3) 8.5 (11.9) 
22 5.5 (7.8) -b 
30 2.8 (4.0) 4.2 (5.9) 
45 2.3 (3.3) 2.2 (3.1) 
60 2.0 (2.8) <LOQc 
90 <LOD 2.8 (4.0) 
120 <LOD <LOQd 
aConcentration µg/mL of compound was determined by UPLC-MS/MS. Concentration in µM 
is given in parentheses. Results are given as a single value for one mouse for each time point. 
LOD = limit of detection; LOQ = Limit of quantitation. bSample was not taken. cConcentration 
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was estimated to 1.8 µg/mL (2.5µM)<LOQ. dConcentration was estimated to 1.7 µg/mL 
(2.4µM)<LOQ. 
 
 
Figure 4. Pharmacokinetics of 16 in mice serum after oral dosing at two concentrations – 400 
and 600 mg/kg. 
 
Obtained in vivo pharmacokinetic properties are summarized in Table 5. In addition, mice 
samples were analyzed for compound 24, monoacetylated analogue and corresponding M+16 
and M+32 metabolites, in order to examine possible deacetylation in the mouse gut. None of 
these metabolites were detected. 
Table 5. In vivo pharmacokinetic properties for 16 in mice after oral administration at two 
different concentrations 
parameter 400 mg/kg dose 600 mg/kg dose 
Tmax (min) 22 15 
Cmax (µM) 7.8 11.9 
AUC0-120 (µM·min) 253 526 
t1/2 (min)
a 43 23 
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time Tc > 3µM (min) >45 >45 
Plasma protein binding (%)b >99% >99% 
a t1/2 (min) values calculated from graph on Fig. 4 using GraphPad Prism 6; 
bAccording to no 
detection of free concentration (ultracentrifugation method, see Materials and Methods) 
 
 
DISCUSSION  
Logical step in the investigation of drug’s anti-BoNT/A potential was the evaluation of the 
candidates in a cell-based assay using mES-MNs, since they mimic the whole intoxication 
process. We proved that our inhibitors protect SNAP-25 from cleavage in a dose-dependent 
manner, when administered prior to holotoxin (Figure 1). Thiophene derivative 96 has shown the 
IC50 = 5-10 µM, benzothiophene derivatives 34 and 38 IC50 = 10-20 µM and among steroidal 
derivatives 16 singled out with IC50 ~ 10 µM. Adamantane derivative 60 seemed to be the 
favorable candidate with 90% of SNAP-25 protection at 20 µM and IC50 < 10 µM. The 
discrepancy between results obtained in proteolytic HPLC-based assay and in mES-MNs for 
cyano derivatives 36, 86 and 87 (61-84% inhibition vs 26-53% SNAP-25 protection at 20 µM) 
could be attributed to their inability to enter the neurons. Regarding compound 38 different MoA 
might be considered since this compound does not act as LC inhibitor (27% inhibition, Table 1) 
but it moderately protects SNAP-25 in mES-MNs in pre-intoxication scenario (IC50 = 10-20 µM, 
Figure 1).  
Pre-exposure model for BoNT/A intoxication is very convenient for discovering drugs with good 
permeability, and the results of inhibitory activities could be useful for prophylactic purposes. 
More significant challenge is post-exposure model, which demonstrates the ability of compound 
to protect SNAP-25 from BoNT/A cleavage after holotoxin endocytosis. Noteworthy results of 
our inhibitors in post-intoxication model in mES-MNs offered us valuable information that 
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newly synthesized derivatives not only enter the cells, but also very probably inhibit to great 
extent the BoNT/A LC inside the neuronal cytosol. From all examined derivatives, we managed 
to select steroidal compound 16 which antagonizes BoNT/A holotoxin up to 89% at 32 µM when 
administered 30 minutes post-intoxication. More importantly, the essential difference between 
our previous hit bis-ACQ compounds came out – compound 1 with < 40% protection failed in 
post-intoxication scenario, thus justifying the synthesis of novel C(3)-amino derivatives. 
In the early stages of drug discovery, the optimization of physicochemical properties (e.g. 
lipophilicity) can greatly improve a compound’s chance in obtaining the proper balance among 
permeability, solubility and metabolism; and the experimental LogD of 2.07 (pH=7.3) obtained 
for compound 16 was considered optimal in that regard.41 Subsequent ADMET and PK studies 
were performed in order to determine if compound 16 was capable of providing adequate drug 
exposure. As supported by its LogD value, compound 16 displayed favorable ADMET 
properties. In an MDR1/MDCK assay it showed permeability constant Papp>20, predictive for 
good tissue penetration and the efflux ratio << 2.5, thus not being a substrate for P-gp. PPB for 
this compound was estimated to >99% according to equilibrium dialysis method, however, 
spectrofluorimetric measurements of 16 binding for HSA and AGP, indicate that interaction 
between 16 and plasma proteins is optimal to enable transport of the drug and to release it at its 
target (Ksv=10
4-106). This experimental observation is supported by detailed reviews on albumin-
drug and AGP-drug interactions.42-44 42,43,44 Due to its nontoxicity in vivo at very high 
concentration (up to 600 mg/kg), we provided pharmacokinetic analysis in mice. Compound 16 
administered at 600 mg/kg dose provides Cmax up to 11.9 µM (8.5 µg/mL, Table 4) and is 
detectable in mouse serum up to 120 min after administration (Figure 4). Unfortunately, detailed 
PK analysis was published only for few inhibitors submitted to in vivo studies, so detailed 
analysis and comparison with 16 is not possible.4  
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CONCLUSION  
Synthesized compounds antagonize BoNT/A LC and BoNT/A in mES-MNs in a dose-dependent 
manner in both pre- and post-intoxication models. To the best of our knowledge, this is the first 
example of LC inhibitors antagonizing BoNT intoxication in mouse ES-cell derived motor 
neurons in a post-exposure model (few SMNPIs of BoNT/A LC active in embryonic chick spinal 
motor neurons were reported previously45). Compound 16 proved to be potent inhibitor of 
BoNT/A holotoxin in mES-MNs in post-intoxication scenario and well tolerated in the mouse up 
to 600 mg/kg, p.o. Binding constants with major transporters in blood (HSA and AGP) are 
within desirable values, suggesting that inspite of high PPB it could be delivered to its target. 
With very good ADMET properties and a plasma Cmax >10 µM in mice after oral 
administration, we believe that compound 16 has distinguished itself from other lead BoNT 
inhibitors in the literature.4 Current efforts are focused on reducing protein binding, 
determining/mitigating the clearance route of 16 in mouse and determining if optimal 
formulation and/or subcutaneous administration could improve its PK profile and merit testing in 
a mouse lethality model.  Noteworthy, there are no post symptomatically administered LC 
inhibitors to date that are significantly efficacious in a mouse model of BoNT intoxication.4  
 
EXPERIMENTAL SECTION 
Chemistry. Melting points were determined on a Boetius PMHK apparatus and were not 
corrected. IR spectra were recorded on a Thermo-Scientific Nicolet 6700 FT-IR diamond crystal 
spectrophotometer. 1H and 13C NMR spectra were recorded on a Varian Gemini-200 
spectrometer (at 200 and 50 MHz, respectively), and a Bruker Ultrashield Advance III 
spectrometer (at 500 and 125 MHz, respectively) in the indicated solvent (vide infra) using TMS 
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as the internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants 
(J) in Hz. ESI–MS (HRMS) spectra of the synthesized compounds were acquired on a Agilent 
Technologies 1200 Series instrument equipped with Zorbax Eclipse Plus C18 (100 × 2.1 mm i.d. 
1.8 µm) column and DAD detector (190-450 nm) in combination with a 6210 Time-of-Flight 
LC/MS instrument in positive and negative ion mode. The samples were dissolved in MeOH 
(HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas temperature 350 
°C; drying gas 12 L min-1; nebulizer pressure 45 psig; fragmentator voltage: 70 V. Mass spectral 
analyses were done using electrospray ionization in positive ion mode on a Surveyor separations 
module coupled to a ThermoFinnigan TSQ AM triple quadrupole mass spectrometer. Gas 
chromatography tandem mass spectrometry (GC-MS) analyses were performed on an Agilent 
7890A GC (Agilent) system equipped with a 5975C inert XL EI/CI MSD and a flame ionization 
detector (FID) connected by capillary flow technology through a 2-way splitter with make-up 
gas. An HP-5 MS capillary column (Agilent Technologies, 25 mm i.d., 30 m length, 0.25 μm 
film thickness) was used. The flash chromatography was performed on Biotage SP1 system 
equipped with UV detector and FLASH 12+, FLASH 25+ or FLASH 40+ columns charged with 
KP-SIL (40 – 63 µm, pore diameter 60 Å), KP-C18-HS (40 – 63 µm, pore diameter 90 Å) or KP-
NH (40 – 63 µm, pore diameter 100 Å) as an adsorbent. Elemental analyses were realized with 
an Elemental Vario EL III microanalyser. Compounds were analyzed for purity (HPLC) using a 
Agilent 1200 HPLC system equipped with Quat Pump (G1311B), Injector (G1329B) 1260 ALS, 
TCC 1260 ( G1316A) and Detector 1260 DAD VL+ (G1315C). Compound 42 was analyzed for 
purity (HPLC) using Waters 1525 HPLC dual pump system equipped with an Alltech, Select 
degasser system, and dual λ 2487 UV-VIS detector. All tested inhibitors were fully characterized 
and their purities were >95% (as determined by HPLC, c.f. Supporting Information). HPLC 
analysis was performed in two diverse systems for each compound. Specific HPLC methods are 
as follows: Method A: Zorbax Eclipse Plus C18 4.6 × 150 mm, 1.8µ, S.N. USWKY01594 was 
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used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in 
water (A) and methanol (B). The analysis were performed at the UV max of the compounds (at 
330 nm for compounds 14-16, 18, 19, 22, 23, 34, 37, 38, 50, 56-65, 66-69, 77-82, 84, 85 and 93, 
and at 254 nm for compound 17) to maximize selectivity. Compounds were dissolved in 
methanol, final concentrations were ~1 mg/mL. Flow rate was 0.5 mL/min. Method B: Zorbax 
Eclipse Plus C18 4.6 x 150 mm, 1.8µ, S.N. USWKY01594 was used as the stationary phase. 
Eluent was made from the following solvents: 0.2% formic acid in water (A) and acetonitrile 
(B). The analysis were performed at the UV max of the compounds (at 330 nm for compounds 
14-19, 22, 23, 34, 37, 38, 44, 50, 56-65, 66-69, 77-82, 84, 85 and 93) to maximize selectivity. 
Compounds were dissolved in methanol, final concentrations were ~1 mg/mL. Flow rate was 0.5 
mL/min. Method C: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was 
used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in 
water (A) and methanol (B). The analysis was performed at the UV max of the compound (at 
330 nm for compounds 20, 21, 24, 43, 44, 47; at 270 nm for compound 30, and at 254 nm for 
compound 33) to maximize selectivity. Compound was dissolved in methanol, final 
concentration was ~1 mg/mL. Flow rate was 0.2 mL/min.  Method D: Zorbax Eclipse Plus C18 
2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the stationary phase. Eluent was made 
from the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis 
was performed at the UV max of the compound (at 254 nm for compounds 20, 24, 33; at 270 nm 
for compound 30 and at 330 nm for compounds 21, 43 and 47) to maximize selectivity. 
Compound was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.2 
mL/min. Method E: Poroshell 120 EC-C18, 4.6 x 50mm, 2.7µ, S.N. USCFU07797 was used as 
the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water 
(A) and acetonitrile (B). The analysis was performed at the UV max of the compound (330 nm 
for compound 48) to maximize selectivity. Compound was dissolved in methanol, final 
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concentration was ~1 mg/mL. Flow rate was 0.5 mL/min. Method F: Poroshell 120 EC-C18, 4.6 
x 50mm, 2.7µ, S.N. USCFU07797 was used as the stationary phase. Eluent was made from the 
following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis was performed 
at the UV max of the compound (330 nm for compound 48) to maximize selectivity. Compound 
was dissolved in methanol, final concentration was ~1 mg/mL. Flow rate was 0.5 mL/min. 
Method G: Symmetry C18, 4.6 x 150 mm, 5 µm, S.N. 021336278136 37 was used as the 
stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) 
and methanol (B). The analysis was performed at the UV max of the compound (340 nm for 
compound 42) to maximize selectivity. Compound was dissolved in methanol, final 
concentration was ~1 mg/mL. Method H: Nucleosil C18, 4 x 150 mm, 5 µm was used as the 
stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) 
and methanol (B). The analysis was performed at the UV max of the compound (340 nm for 
compound 42) to maximize selectivity. Compound was dissolved in methanol, final 
concentration was ~1 mg/mL.  
Procedure A: General procedure for the synthesis of N-Cbz protected aminoquinolines 107 
and 109.
13 The mixture of 4,7-dichloroquinoline/4-chloroquinoline (1 equiv) and mono-Cbz 
protected diaminoalkane (1.1 – 1.2 equiv) was slowly heated to 80 °C for 1 h, and the mixture 
was continued for 6-8 h at 120-130 °C. After cooling to r.t., reaction mixture was transferred to 
the separation funnel using CH2Cl2/1M NaOH. The organic layer was washed with 1M NaOH, 
water and brine. The organic layer was dried over anhydrous Na2SO4 and solvent was evaporated 
under reduced pressure. Crude product was purified using column chromatography. 
Procedure B: General procedure for the obtainment of steroidal derivatives 4-11 and 29.
16
 
Alcohol (1 equiv) was dissolved in CH2Cl2. PCC (1.5 equiv) was added, and the mixture was 
stirred at r.t. for 3.5 h. Reaction mixture was filtered through a short column of SiO2 (eluent 
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CH2Cl2/EtOAc = 7/3). Crude aldehyde was dissolved in dry MeOH, aminoquinoline (1.5 equiv) 
was added, and mixture was stirred at r.t. overnight. NaBH4 (2 equiv) was added, and stirring 
was continued at r.t. for 12 h. Solvent was removed under reduced pressure and crude mixture 
was prepared for column purification. 
Procedure C: General procedure for the removal of the Boc-protecting groups with TFA 
for compounds 14-23 and 30. A solution of the N-Boc-protected amine in TFA/CH2Cl2 (v:v; 
1:10), was stirred at r.t. for 6 h. Solvents were evaporated under reduced pressure and the residue 
was treated with CH2Cl2/2.5M NaOH. The organic layer was dried over MgSO4, and the solvent 
was evaporated under reduced pressure.  
Procedure D: General procedure for N-methylated aminoquinolines 12, 13, 37, 38, 48, 56-
65, 68, 69 and 84, 85.
46
 To a stirred solution of aminoquinolines (1 equiv) in MeOH containing 
37% aqueous formaldehyde (2 equiv), the mixture of ZnCl2 (2 equiv) and NaHB3CN (4 equiv) in 
MeOH was added. After the reaction mixture was stirred at r.t. for 4 h, the solution was taken up 
in 0.1 M NaOH and most of MeOH was evaporated under reduced pressure. Aqueous solution 
was extracted with CH2Cl2, the combined extracts were washed with water and brine and dried 
over anhydrous Na2SO4. The solvent was evaporated under reduced pressure. 
Procedure E: General procedure for reductive amination to produce compounds 33, 34, 42-
45, 50, 66 and 67. Amine (1.5 equiv) and appropriate aldehyde (1 equiv) were dissolved in 
MeOH/CH2Cl2 mixture (v:v; 2:1), glac. AcOH (1.5 equiv) was added, and the mixture was 
stirred under Ar atmosphere at r.t. After 3 h, NaBH4 (6 equiv) was added, and stirring was 
continued for another 18 h. Solvent was removed under reduced pressure, and the residue was 
dissolved in CH2Cl2. The organic layer was washed with 2M NH4OH, water and then extracted 
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with CH2Cl2. The combined organic layers were washed with brine and dried over anh. Na2SO4. 
Finally, the solvent was evaporeted under reduced pressure. 
Procedure F: General procedure for the Suzuki coupling reaction using PdO × 1.4 H2O for 
compounds 40 and 113.
47
 An appropriate aryl-bromide (1 equiv) was added to the mixture of 
arylboronic acid (1.2 equiv), catalyst PdO × 1.4 H2O (0.1 equiv), K2CO3 (1.2 equiv) and 
EtOH/H2O (3:1, v/v). The mixture was stirred at 60 °C for 5 h, then diluted with water and 
extracted with CH2Cl2. Combined organic layers were washed with brine and dried over anh. 
Na2SO4. After filtration, the solvent was removed under reduced pressure. The product was 
purified using silica gel flash chromatography. 
Procedure G: General procedure for the Suzuki coupling reaction using Pd(OAc)2 and 
PPh3 for compounds 49 and 111. The solution of Pd(OAc)2 (0.1 equiv) and PPh3 (0.4 equiv) in 
DME was purged with argon and stirred at r. t. for 10 min. An appropriate arylboronic acid (1 
equiv) and 2M aq. Na2CO3 were added. After 5 min, aryl-bromide (1 equiv) was added. The 
mixture is once more purged with Ar and heated in a sealed vessel in microwave reactor at 80 °C 
for 3h. The reaction mixture was cooled and extracted with ethyl-acetate. The combined organic 
layers were washed with brine and dried over anh. Na2SO4. After filtration, the solvent was 
removed under reduced pressure. The crude product was further purified in a manner provided 
for each compound. 
Procedure H: General procedure for palladium catalyzed amination of quinolines to 
produce compounds 78, 79, 81 and 82. Vial was charged with mixture of Pd(OAc)2 (4 mol %) 
and DPEphos (8 mol %)/SPhos (8 mol %) in dioxne and stirred for a few minutes in Ar 
atmosphere on room temperature. Subsequently, haloquinoline (1.0 equiv), amine (1.2 equiv) 
and K3PO4 (2.5 equiv) were added in to reaction mixture.The resulting suspension was sparged 
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with argon for several minuties. The vial was quickly capped, heated to 85 oC over the night and 
then cooled down to room temperature. The mixture was adsorbed onto silica gel and purified. 
N-(quinolin-4-yl)ethane-1,2-diamine (AQ11), N-(7-chloroquinolin-4-yl)butane-1,4-diamine 
(AQ4), N-(7-chloroquinolin-4-yl)hexane-1,6-diamine (AQ6), N-(quinolin-4-yl)propane-1,3-
diamine (AQ7), N-(quinolin-4-yl)butane-1,4-diamine (AQ8), N-(quinolin-4-yl)hexane-1,6-
diamine (AQ9), N-quinolin-4-yldecane-1,10-diamine (AQ12) were prepared according to known 
procedures.48-51 48,49,50,51 
 
In vitro HPLC-based Proteolytic Assay for BoNT/A LC Inhibition. BoNT/A LC 17-mer 
HPLC endpoint assay in 96well plate (manual method) uses 2.5mM stock solution of the 17-mer 
peptide (termed P39, acetyl-SNKTRIDEANQRATKML-amide) in 50 mM HEPES, pH 7.4 For 
the inhibitor, the final concentration was 20 µM, diluted from a working stock of 120 µM in 50 
m M HEPES pH 7.4. Just prior to conducting the assay, LcA was diluted to 0.1 mg/mL in 50 
mM HEPES pH 7.4 and kept on ice. Final concentrations for the assay are as follows: [LcA] = 
1.95 µg/mL (20 nM), [BSA] = 0.2 mg/mL, [P39] = final conc. 0.25mM, [Inhibitor] = 20 µM in a 
total reaction volume of 30 µL. The assay is conducted as follows. The compound (5 µl of the 
120 µM working stock) is incubated with the LcA master mix (LcA and BSA in 50mM HEPES) 
and incubated for 10 minutes at room temperature. The P39 substrate is then added and the 
samples are incubated at 37°C for 10 minutes. Cleavage products of the P39 substrate are 
monitored and quantitated using a Shimadzu Prominence ultra-fast liquid chromatography 
(UFLC) XR system using a Hypersil Gold Javelin (Thermo Fisher Scientific, Waltham, MA) c18 
guard column and a Hypersil Gold (Thermo Fisher Scientific, Waltham, MA) c18 reverse-phase 
analytical column (50 × 2.1 mm, 1.9 µm). Flow rate of 1.000 ml/min. Column chamber oven 
temp 65⁰C. Monitor absorbance at 214 nm and 280 nm. The solvents and gradient are as follows: 
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Buffer A = HPLC grade water + 0.05% Trifluoroacetic acid; Buffer B= 50% HPLC grade 
Acentonitrile + 0.05% Trifluoroacetic acid. All HPLC separations were conducted and peak 
areas measured with the LC solution automated integration software (Shimadzu Corporation, 
Kyoto, Japan). For BoNT/A, the fragment peaks retention times were ≈ ( 0.9-1.1 min) and (1.3-
1.5 min). Percent inhibition of each compound tested was calculated using the following 
formula: 100-(∑of fragment peak areas + compound/ ∑of fragment peak areas – compound) × 
100. 
Derivation of motor neurons from mouse embryonic stem cells. We have utilized a specific 
mouse embryonic stem (ES) cell (HBG3) line, in which mouse motor neuron specific Hb9 
promotor drives eGFP expression, to generate motor neurons. The specifics regarding the 
culture, differentiation and maintenance of these cells, and the characterization of derived motor 
neurons have been published.52,53  
BoNT intoxication, Inhibitor Application and Western blot analysis for the BoNT mediated 
SNAP-25 cleavage determination. For pre-intoxication studies, the motor neurons 
differentiated from mouse ES cells were cultured in 24-well plates and treated with the indicated 
amounts of compounds in the figures. Following a 30 min incubation, the cultures were 
intoxicated with 500 pM BoNT/A (MetaBiologics, Madison, WI). For post-intoxication studies, 
the cultures were first intoxicated with 500pM BoNT/A and then the compounds were applied to 
the plates 30 or 60 min after the intoxication. In both pre- and post-intoxication models, total 
intoxication time was kept constant as 4 hours and the neurons were maintained at 37 °C cell 
culture humidified incubators with 5% CO2 atmosphere. The cells were then washed with PBS 
thoroughly, and lysed in NP-40 cell lysis buffer. The extent of SNAP-25 cleavage was quantified 
using standard immunoblotting procedures with SNAP-25 antibodies that detect both the full 
length and the BoNT/A cleaved large fragment, as described previously.7,10 Briefly, the cell 
lysates were processed, run on 12% Tris Glycine gels (Invitrogen, #XP00125), and transferred to 
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nitrocellulose membranes. Membranes were blocked in 5% non-fat milk for 1hr, and then 
incubated with primary antibodies against GAPDH (Millipore, #MAB374), and SNAP-25 
(BioLegend, SMI-81, #836304) in TBST buffer containing 5% milk overnight at 4 °C. Horse 
radish peroxidase conjugated secondary antibodies (Millipore) were utilized for the detection of 
the signal. The blots were visualized with Pierce ECL Western detection kit, using a gel 
documentation and analysis system.  
LogD (shake-flask) metod. Standard shake-flask method was used for logD (pH 7.31, 30 mM 
TBS) determination.37-39 37,38,39 Stock solution of 16 was prepared in octanol (c= 2.5×10-3 M). 
Toxicity studies: in vivo. Groups of five healthy mice were treated per os (p.o.) for three 
consecutive days with aminoquinolines suspended in 0.5% hydroxyethylcellulose-0.1% Tween 
80, previously dissolved in DMSO. Individual mouse behavior and appearance was monitored 
two times a day for 30 days. Compounds proved to be non-toxic if all 5 mice survived 30 days 
after administration and showed normal appearance and behavior. 
The study followed the International Guiding Principles for biomedical research involving 
animals, and was reviewed by a local Ethics Committee and approved by the Veterinary 
Directorate at the Ministry of Agriculture and Environmental Protection of Serbia (decision no. 
323-07-02444/2014-05/1). 
In vitro Plasma Protein Binding (Equilibrium dialysis for 16). In vitro plasma protein 
binding was performed by the ADME Center at USAMRICD using Thermo Scientific’s protocol 
and their Single-Use RED (rapid equilibrium dialysis) Plates. Samples (100-500µL) were 
prepared by spiking test compound with plasma at the appropriate concentrations and places into 
the sample chamber. Dialysis buffer (300-750 µL) was added to the buffer chamber. The unit 
was covered with sealing tape and incubated at 37°C on an orbital shaker at approximately 250 
rpm or 20 rpm on an up-and-down shaker for 4h. 50 µL from both the buffer and the plasma 
chambers were placed in separate microcentrifuge tubes or into a deep-well plate for analysis. 50 
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µL of plasma was added to the buffer sample and an equal volume of buffer to the collected 
plasma sample. 300 µL of Internal Standard containing precipitation buffer (such as cold 90/10 
acetonitrile/water with 0.1% formic acid) was added to precipitate protein and release compound. 
Vortexed and incubated 30 minutes on ice, centrifuged for 10 minutes at 13,000-15,000 × g. The 
supernatant was analyzed with LC-MS/MS. The test compound concentration in the buffer and 
plasma chambers were determined from peak areas relative to the internal standard. The 
percentage of the test compound bound was calculated as follows: % Free = (Concentration 
buffer chamber/Concentration plasma chamber) × 100%. % Bound = 100% - % Free. 
In vitro Plasma Protein Binding (Spectrofluorimetric determination for compound 16). 
Human serum albumin (HSA), alpha-1-acid glycoprotein (AGP), potassium dihydrogen 
phosphate, disodium hydrogen phosphate, sodium chloride, potassium chloride and DMSO were 
purchased from Sigma-Aldrich.  Fluorescence spectra were recorded on Horiba Jobin Yvon 
Fluoromax-4 spectrometer, equipped with Peltier element and magnetic stirrer for cuvette, using 
quartz cell with 1 cm path length and 4 mL volume. UV-Vis spectra were recorded on Thermo 
scientific spectrophotometer evolution 60s using quartz cell with 1 cm path length and 4 mL 
volume. All UV/Vis spectra were recorded against the corresponding blank in the 200-500 nm 
wavelength range, with 500 nm/min scan speed. pH Values were potentiometrically measured 
using Crison pH-Burette 24 2S equipped with a micro-combined pH electrode (Crison pH 
electrode 50 29). The pH electrode was calibrated by standard Crison buffer solutions (pH 4.01, 
7.00, and 9.21). Stock solutions of AGP (c=6.05×10-5 M) and HSA (c=1.91×10-4 M) were 
prepared in PBS (1X, pH 7.34) and kept in the refrigerator. Stock solution of 16 (c=4.28×10-4 M) 
was prepared in DMSO. For protein–16 interaction studies, protein solutions were freshly 
prepared from the stock, by dilution with a buffer (AGP and HSA concentration was kept 
constant, c=5×10-7 M), and titrated with compound stock solution (from 1 to 20 
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compound/protein molar ratio). During the titration, the solutions were stirred and thermostated 
(t=25.0±0.1°C, regulated by Peltier element). The equilibration time between increment 
additions was 10 minutes. An excitation wavelength was 280 nm, with 5 nm slits; emission 
spectra were recorded in 300-450 nm wavelength range, with 5 nm slits, and 0.1 s integration 
time. Background PBS signal was subtracted from each spectrum. Fluorescence intensities were 
corrected for inner filter effect by measuring absorbances at excitation and emission wavelength.  
In vivo Mouse Pharmacokinetics. Compound 16 was dissolved in DMSO, suspended in 0.5% 
hydroxyethylcellulose – 0.1% Tween 80 in water and administered orally at two different 
concentrations. Blood was collected from one mouse, previously anaesthetized with chloroform, 
for each time point via cardiac puncture. Samples were immediately centrifuged and serum 
stored at -20 °C until the moment of analysis. Human serum was collected from a healthy 
volunteer and stored in refrigerator at 4 °C. Total concentrations of compound in mice samples 
were determined by precipitation of proteins by addition of two volume equivalents of 
acetonitrile (50 µL of sample and 100 µL of acetonitrile), following 15 seconds on vortex and 30 
minutes in ultrasound bath. After centrifugation of denatured proteins (10 minutes, 13400 rpm), 
supernatants were injected. For determination of free concentration, ultracentrifugation method 
was used. 150 µL of mice samples were centrifuged on Beckman Coulter ultracentrifuge (rotor 
type SW55 Ti, 25 000 rpm, 24 h, 4 °C, 0.8 mL tubes). Mice serum has been separated into three 
layers, 30 µL of transparent middle layer was taken from each tube via syringe and injected into 
UPLC-MS/MS. Transparent middle layer showed 1% of starting plasma proteins, as confirmed 
by BCA method for determination of concentration of proteins. Calibration curves for free and 
total concentrations were prepared using blank human serum. In case of total concentration, 
compound standard solutions were prepared in DMSO (250 and 2500 µg/mL). Human serum 
was spiked with stock solutions, final solutions (1 – 25 µg/mL) were incubated at 37 °C for 1 h 
and treated with acetonitrile in the same way. For determination of free concentration of the 
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drug, ultracentrifugation method was used. Standard solutions of compound (0.5 – 10 µg/mL) 
were prepared in supernatants obtained by ultracentrifugation of blank human serum. From both 
experiments, 15-45 min samples were centrifuged on Beckman Coulter ultracentrifuge (rotor 
type SW55 Ti, 24 h, 4 °C, 25000 rpm, 0.8 mL tubes) and analyzed for compound 16. 
Concentrations of compound in mice serum were quantitated using a Waters Acquity UPLC H-
Class (WAT-176015007) (Milford, MA,USA) with Poroshell 120 EC-C18 column (4.6 × 50mm, 
2.7µ, S.N. USCFU07797) and interfaced to mass detector (Waters TQ (Tandem Quadrupole, 
WAT-176001263)). Single ion recording experiment (SIR) was used, by monitoring three ions: 
[M+H]1+ (709), [M+2H]2+ (355) and [M+3H]3+ (237).  Column temperature was maintained at 
40 °C and mobile phase flow rate at 0.3 mL/min. The mobile phase consisted of ultrapure water 
(TKA Germany MicroPure water purification system, 0.055 µS/cm) containing 0.2 vol.% formic 
acid (solvent A) and acetonitrile (solvent B), with a gradient 0-2 min 5%B, 2-8 min 5%B→ 
95%B, 8-12 min 95%B, 12-12.5 min 95%B→ 5%B, 12.5-15 min 5%B for reconditioning of the 
column. Injection volume was 10 µL. For detection of total concentration, limit of detection 
(LOD) was 1 µg/mL (S/N > 3:1), limit of quantitation (LOQ) was 2 µg/mL (S/N ≥ 10:1) and 
R2=0.9952 (calibration curve was performed in triplicate).  
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